Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSQDLE)

• Drug Name: Flecainide Drug Info
• Synonyms: flecainide; 54143-55-4; Flecaine; Tambocor; Flecainida; Flecainidum; (+-)-Flecainide; Flecainidum [INN-Latin]; Flecainida [INN-Spanish]; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; Flecainide [INN:BAN]; CCRIS 313; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; C17H20F6N2O3; CHEMBL652; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; CHEBI:75984; DJBNUMBKLMJRSA-UHFFFAOYSA-N; NCGC00015443-06; DSSTox_CID_3054; DSSTox_RID_76854; DSSTox_GSID_23054; (-)-Flecainide; Flecaine; Almarytm (TN); Apocard (TN); Ecrinal (TN); Flecainide (INN); Tambocor (TN); N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; Ic Flecainide

Indication

Disease Entry	ICD 11	Status	REF
Tachyarrhythmias	BC71	Approved	[1]
Paroxysmal atrial fibrillation	BC81.30	Phase 1	[2]
Atrial fibrillation	BC81.3	Investigative	[3]

• Therapeutic Class: Antiarrhythmic Agents
• Cross-matching ID:
  PubChem CID: 3356
  ChEBI ID: CHEBI:75984
  CAS Number: CAS 54143-55-4
  TTD Drug ID: DMSQDLE
  VARIDT Drug ID: DR00512
  INTEDE Drug ID: DR0700
  ACDINA Drug ID: D00278

Molecule-Related Drug Atlas

Drug(s) Targeting E3 ubiquitin-protein ligase COP1 (RFWD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[4]
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[4]
Propafenone	DMPIBJK	Tachyarrhythmias	BC71	Approved	[4]
Tocainide	DMYNMDP	Ventricular arrhythmias	BC71	Approved	[4]
Barucainide	DMTMS3L	Heart arrhythmia	BC65	Terminated	[10]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.9 (SCN11A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[11]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[12]
Lacosamide	DMVM6QR	Convulsion	8A68.Z	Approved	[13]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[14]
Tolperisone	DMA2GHJ	Muscle spasm	MB47.3	Approved	[15]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[13]
Oxcarbazepine	DM5PU6O	Epilepsy	8A60-8A68	Approved	[16]
HP-184	DMNOMV2	Multiple sclerosis	8A40	Phase 2	[17]
QX-314	DMAV2FM	Pain	MG30-MG3Z	Terminated	[18]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[19]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[20]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[21]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[22]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[24]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[26]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[27]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[28]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[29]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[31]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[32]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[33]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[34]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[35]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[36]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[37]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[38]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[39]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[40]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[41]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[42]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[43]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[44]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[45]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[46]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[47]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[48]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[49]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[50]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[51]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[52]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[53]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[53]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[54]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[55]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[56]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[57]
Cisapride	DMY7PED	Gastroesophageal reflux disease	DA22.Z	Approved	[58]

Drug(s) Affected By Sodium channel protein type 5 subunit alpha (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[9]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[59]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[60]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[61]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[62]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[63]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[66]
Luvox	DMJKROX	Anxiety disorder	6B00-6B0Z	Approved	[67]

Drug(s) Affected By Nuclear protein 1 (NUPR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[68]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[7]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[69]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[7]

Drug(s) Affected By Alpha-1-antichymotrypsin (SERPINA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[69]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[73]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[74]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]

Drug(s) Affected By Fatty acid-binding protein, liver (FABP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[75]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[69]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[76]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[77]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[7]

Drug(s) Affected By Asparagine synthetase (ASNS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[78]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[79]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[80]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[81]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[7]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[82]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[83]

Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[84]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[85]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[69]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[86]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[87]

Drug(s) Affected By Inhibin beta E chain (INHBE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[69]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[88]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[7]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[6]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[89]

Drug(s) Affected By Acid ceramidase (ASAH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[90]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[7]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[91]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[7]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[92]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[7]

Drug(s) Affected By Lysophospholipase D GDPD3 (GDPD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[69]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[7]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[7]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[93]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[94]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[94]
Haloperidol	DM96SE0	Delirium		Approved	[7]

Drug(s) Affected By Protein DEPP1 (DEPP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[7]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[95]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[96]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[7]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[7]

Drug(s) Affected By Serine protease hepsin (HPN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Selenium	DM25CGV	N. A.	N. A.	Approved	[97]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[7]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[98]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[99]

Drug(s) Affected By Lanosterol synthase (LSS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[100]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[101]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[88]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[7]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[6]

Drug(s) Affected By AP-1 complex subunit sigma-1A (AP1S1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[7]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[103]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[99]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[104]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[105]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[69]

Drug(s) Affected By Transgelin (TAGLN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[106]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[69]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[107]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[108]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[69]

Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[109]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[110]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[111]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[100]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[7]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[112]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[70]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]

Drug(s) Affected By Fibronectin type III domain-containing protein 4 (FNDC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[6]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[6]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[6]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[6]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[7]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]
Haloperidol	DM96SE0	Delirium		Approved	[7]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[99]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[113]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[6]

Drug(s) Affected By Protein c-Fos (FOS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[114]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[115]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[116]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[117]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[116]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[118]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[119]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[120]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[121]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[122]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[123]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[124]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[125]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[126]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[127]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[128]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[129]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[130]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[131]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[132]

Drug(s) Affected By Caspase-7 (CASP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[133]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[117]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[134]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[135]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[8]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[8]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[136]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[137]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[138]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[139]

Drug(s) Affected By Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[140]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[141]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[142]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[89]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[143]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[144]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[145]
aconitine	DMFOZ60	Discovery agent	N.A.	Investigative	[146]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[147]

Drug(s) Affected By Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[148]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[148]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[9]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[96]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[149]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[150]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[113]
Mepivacaine	DMH2NMY	Analgesia	MB40.8	Approved	[149]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[151]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[151]

Drug(s) Affected By Potassium voltage-gated channel subfamily E member 1 (KCNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[83]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[152]
Pentobarbital	DMFNH7L	Brain ischaemia	8B1Z	Approved	[153]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[9]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[9]
Diltiazem	DMAI7ZV	Angina pectoris	BA40	Approved	[9]
Sotalol	DML60TN	Sinus rhythm disorder	BC9Y	Approved	[9]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[9]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[9]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
E3 ubiquitin-protein ligase COP1 (RFWD2)	TT05DLS	COP1_HUMAN	Modulator	[4]
Voltage-gated sodium channel (Nav)	TTIG65Q	NOUNIPROTAC	Modulator	[4]
Voltage-gated sodium channel alpha Nav1.9 (SCN11A)	TTN9VTF	SCNBA_HUMAN	Blocker	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[5]
Cytochrome P450 1A2 (CYP1A2) Main DME	DEJGDUW	CP1A2_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[6]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[6]
AP-1 complex subunit sigma-1A (AP1S1)	OTQ2H8DN	AP1S1_HUMAN	Gene/Protein Processing	[7]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Gene/Protein Processing	[6]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[8]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Gene/Protein Processing	[8]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[9]
Fatty acid-binding protein, liver (FABP1)	OTR34ETM	FABPL_HUMAN	Gene/Protein Processing	[6]
Fibronectin type III domain-containing protein 4 (FNDC4)	OTOQK0WK	FNDC4_HUMAN	Gene/Protein Processing	[7]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Gene/Protein Processing	[6]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2560).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
• [6] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [7] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [8] Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
• [9] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [10] Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle. Am Heart J. 1990 May;119(5):1050-60.
• [11] Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
• [12] The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
• [13] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [14] Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
• [15] Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
• [16] Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
• [17] Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
• [18] Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
• [19] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [20] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [21] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [22] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [23] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [24] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [25] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [26] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [27] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [28] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [29] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [30] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [31] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [32] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [33] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [34] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [35] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [36] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [37] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [38] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [39] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [40] Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
• [41] Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
• [42] Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
• [43] Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
• [44] Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
• [45] Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
• [46] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [47] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [48] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
• [49] Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
• [50] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [51] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [52] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [53] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [54] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [55] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [56] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [57] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
• [58] The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J Biol Chem. 2002 Feb 15;277(7):4989-98. doi: 10.1074/jbc.M107345200. Epub 2001 Dec 10.
• [59] Ethnic-Related Sodium Voltage-Gated Channel Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Na(v)1.5. Mol Pharmacol. 2021 Jun;99(6):448-459. doi: 10.1124/molpharm.120.000176. Epub 2021 Apr 6.
• [60] Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
• [61] Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
• [62] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [63] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [64] Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
• [65] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [66] Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.
• [67] Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine. Europace. 2010 Feb;12(2):282-3. doi: 10.1093/europace/eup332. Epub 2009 Oct 29.
• [68] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [69] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [70] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [71] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [72] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [73] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [74] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [75] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [76] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [77] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [78] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [79] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [80] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [81] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [82] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [83] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [84] Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. Biochem J. 1993 Mar 15;290 ( Pt 3)(Pt 3):701-6. doi: 10.1042/bj2900701.
• [85] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [86] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [87] Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
• [88] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [89] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [90] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [91] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [92] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [93] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [94] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [95] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [96] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [97] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [98] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [99] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [100] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [101] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [102] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [103] An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
• [104] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [105] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [106] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [107] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
• [108] Differentiation of human embryonic stem cells into smooth muscle cells in adherent monolayer culture. Biochem Biophys Res Commun. 2006 Dec 15;351(2):321-7. doi: 10.1016/j.bbrc.2006.09.171. Epub 2006 Oct 17.
• [109] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [110] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [111] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [112] Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
• [113] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [114] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [115] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [116] Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
• [117] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [118] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [119] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [120] Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
• [121] Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
• [122] The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
• [123] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [124] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [125] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [126] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [127] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [128] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [129] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [130] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [131] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [132] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [133] Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. Pharmaceutics. 2021 Sep 7;13(9):1415. doi: 10.3390/pharmaceutics13091415.
• [134] A model to identify novel targets involved in oxidative stress-induced apoptosis in human lung epithelial cells by RNA interference. Toxicol In Vitro. 2010 Feb;24(1):310-8. doi: 10.1016/j.tiv.2009.08.008. Epub 2009 Aug 23.
• [135] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [136] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [137] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [138] Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010 Jul;95(7):3453-9. doi: 10.1210/jc.2010-0072. Epub 2010 Apr 28.
• [139] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [140] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [141] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [142] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [143] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [144] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [145] Cellular reactions to long-term volatile organic compound (VOC) exposures. Sci Rep. 2016 Dec 1;6:37842. doi: 10.1038/srep37842.
• [146] Notch1-mediated histone demethylation of HCN4 contributes to aconitine-induced ventricular myocardial dysrhythmia. Toxicol Lett. 2020 Jul 1;327:19-31. doi: 10.1016/j.toxlet.2020.03.017. Epub 2020 Mar 28.
• [147] Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
• [148] Additional gene variants reduce effectiveness of beta-blockers in the LQT1 form of long QT syndrome. J Cardiovasc Electrophysiol. 2004 Feb;15(2):190-9. doi: 10.1046/j.1540-8167.2004.03212.x.
• [149] Long QT 1 mutation KCNQ1A344V increases local anesthetic sensitivity of the slowly activating delayed rectifier potassium current. Anesthesiology. 2006 Sep;105(3):511-20. doi: 10.1097/00000542-200609000-00015.
• [150] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [151] Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
• [152] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [153] Inhibition of cardiac potassium currents by pentobarbital. Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):29-37. doi: 10.1007/s00210-001-0490-1. Epub 2001 Nov 8.